Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Shares, par value (euro)0.12 per share
-
Shares outstanding
-
22,421,536
-
Number of holders
-
86
-
Total 13F shares, excl. options
-
35,746,141
-
Shares change
-
-878,995
-
Total reported value, excl. options
-
$372,596,379
-
Value change
-
-$7,716,451
-
Put/Call ratio
-
60%
-
Number of buys
-
50
-
Number of sells
-
-35
-
Price
-
$10.42
Significant Holders of CureVac N.V. - Common Shares, par value (euro)0.12 per share (CVAC) as of Q2 2023
105 filings reported holding CVAC - CureVac N.V. - Common Shares, par value (euro)0.12 per share as of Q2 2023.
CureVac N.V. - Common Shares, par value (euro)0.12 per share (CVAC) has 86 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35,746,141 shares
.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (12,245,955 shares), Avidity Partners Management LP (4,300,000 shares), PRICE T ROWE ASSOCIATES INC /MD/ (3,564,026 shares), CITADEL ADVISORS LLC (2,353,800 shares), MILLENNIUM MANAGEMENT LLC (1,883,659 shares), BlackRock Inc. (1,843,374 shares), Bill & Melinda Gates Foundation (1,625,943 shares), Camber Capital Management LP (1,462,500 shares), Alyeska Investment Group, L.P. (899,423 shares), and Balyasny Asset Management L.P. (624,878 shares).
This table shows the top 86 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.